In addition, Camidanlumab tesirine, also known as ADCT-301, is an ADC in phase 1/2 for the treatment of classical Hodgkin’s lymphoma (cHL) and non-HL (NCT02432235) (Hamadani et al., 2021), and CD276, an immune checkpoint overexpressed during pathologic angiogenesis and an interesting candidate target of different ADCs in advanced solid tumors (NCT04145622, NCT03729596 and NCT03595059) (Ceci et al., 2022; Ziogas et al., 2023). The gene discussed is CD276; the disease is Hodgkins lymphoma.